Nova IVF Fertility, India’s fastest-growing fertility chain, has integrated Artificial Intelligence (AI) into its IVF labs to bring greater precision, transparency, and trust to embryo selection—one of the most critical steps in fertility treatment. Through a partnership with Kai Health, a leading South Korean AI technology firm, Nova IVF will implement Vita Embryo, an AI-based embryo assessment tool, across its 120 clinics in 65 cities.
This advanced technology aims to improve pregnancy rates, shorten IVF cycles, and enhance transparency, providing couples with greater confidence in their fertility journey.
AI Strengthens the IVF Journey
Embryo selection is the defining moment in an IVF cycle. Traditionally, clinical embryologists use years of expertise to grade embryos based on their potential to develop into a pregnancy. With AI serving as an additional “pair of eyes,” embryo evaluation now gains an extra layer of accuracy.
AI-powered systems can detect subtle details about embryo health that may be invisible to the human eye, ensuring couples receive the best possible embryo for transfer. This not only improves success rates but also reduces uncertainty for patients undergoing treatment.
Expanding AI Integration Across Nova IVF Clinics
Nova IVF Fertility, operated by Asia Healthcare Holdings, performs more than 20,000 IVF cycles annually through its extensive network of over 120 clinics, supported by 120+ fertility specialists and 150+ embryologists.
Currently, Vita Embryo has been introduced in 20 locations, with full-scale adoption expected across all clinics by the end of the year. This initiative underscores Nova IVF’s leadership in adopting global standards, as its IVF labs already follow European embryology protocols.
Leadership Speaks: AI as a Game-Changer
Commenting on the development, Mr. Shobhit Agarwal, CEO of Nova IVF Fertility, said:
“With fertility rates declining in India and 1 in 6 couples struggling to conceive, precision in treatment is the need of the hour. By integrating AI, we aim to improve successful pregnancy outcomes and reduce the turnaround time of IVF cycles. The technology also minimizes the number of embryos required for transfer, addressing ethical concerns linked to multiple pregnancies. Importantly, we are committed to making these advancements accessible to patients in both metros and tier-2 cities—without any additional charges.”
Kai Health Brings Global AI Expertise
Dr. Hyejun Lee, CEO of Kai Health, highlighted the clinical impact of AI:
“Our research shows that AI increases the precision of embryo selection by 12%. Partnering with Nova IVF Fertility reflects our readiness for global market expansion. We remain focused on technological excellence and clinical outcomes by collaborating with leading IVF networks worldwide.”
As per the press release, Kai Health has already attained medical device certification for Vita Embryo. The certifications cover Europe, Singapore, Korea, and India. Clinical trials demonstrate that the AI-powered system can double the accuracy of embryo selection compared to human evaluation. This offers couples significantly better chances of achieving a successful pregnancy.
Key Highlights of AI in IVF at Nova Clinics
- AI and Big Data enable highly accurate embryo analysis.
- Clinical tests show a 12% increase in precision of embryo selection with AI.
- Faster embryo selection reduces time in IVF cycles.
- Greater transparency improves patient confidence.
A Milestone in Fertility Care
By integrating AI into its IVF labs, Nova IVF Fertility is advancing clinical precision. It is also reinforcing its mission to make cutting-edge technology accessible to all patients. This partnership with Kai Health marks a milestone in India’s fertility care. It paves the way for higher success rates, shorter treatment cycles, and greater patient trust